Recombinant Proteins
Product List
HAPLN1 Human, HEK
Hyaluronan And Proteoglycan Link Protein 1 Human Recombinant, HEK
HAPLN1 Human Recombinant produced in HEK293 Cells.is a single, glycosylated polypeptide chain containing 345 amino acids (16-354 a.a.) and having a molecular mass of 39.3kDa. HAPLN1 is fused to a 6 amino acid His-tag at C-terminus and is purified by proprietary chromatographic techniques.
SCN3B Human
Sodium Channel Voltage-Gated, Type III Beta Human Recombinant
SCN3B is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
HAUS1 Human
HAUS Augmin-Like Complex, Subunit 1 Human Recombinant
HAUS1 is fused to a 24 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
SCN3B Human, Sf9
Sodium Channel Voltage-Gated, Type III Beta Human Recombinant, Sf9
SCN3B Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 146 amino acids (23-159a.a.) and having a molecular mass of 16.8kDa (Molecular size on SDS-PAGE will appear at approximately 18-28kDa).
SCN3B is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Sf9, Baculovirus cells.
SCO1 Human
SCO Cytochrome Oxidase Deficient Homolog 1 Human Recombinant
HAX1 Human
HCLS1 Associated Protein X-1 Human Recombinant
SCP2D1 Human
SCP2 sterol-binding domain containing 1 Human Recombinant
HCST Human
Hematopoietic Cell Signal Transducer Human Recombinant
HCST produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 271 amino acids (20-48 a.a.) and having a molecular mass of 30.1kDa. (Molecular size on SDS-PAGE will appear at approximately 28-40kDa).
HCST is expressed with a 242 amino acid hIgG-His-tag at C-Terminus and purified by proprietary chromatographic techniques.
Sf9, Baculovirus cells.
SCRN1 Human
Secernin 1 Human Recombinant
HEBP1 Human
Heme Binding Protein 1 Human Recombinant
HEBP1 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Introduction
The term “Other” can be defined in various contexts. In a general sense, it refers to something or someone that is different or distinct from the one already mentioned or known . In biological taxonomy, classification involves organizing living organisms into hierarchical categories based on their characteristics and evolutionary history .
Biological properties of “Other” can be understood through key characteristics shared by living organisms, such as order, sensitivity or response to stimuli, reproduction, growth and development, regulation, homeostasis, and energy processing . These properties are expressed in various patterns and distributed across different tissues, contributing to the organism’s overall function and survival.
The primary biological functions of “Other” include catalyzing chemical reactions, synthesizing and repairing DNA, transporting materials across cells, receiving and sending chemical signals, responding to stimuli, and providing structural support . These functions play crucial roles in immune responses and pathogen recognition, ensuring the organism’s defense mechanisms are active and effective .
Modes of action describe the functional or anatomical changes resulting from exposure to a substance. This includes the interaction with other molecules and cells, binding partners, and downstream signaling cascades . For example, a mode of action could involve binding to DNA, leading to transcriptional regulation .
Regulatory mechanisms control the expression and activity of “Other” through transcriptional regulation and post-translational modifications . These mechanisms ensure that the biological processes are carried out efficiently and accurately, adapting to the organism’s needs and environmental changes.
In biomedical research, “Other” has various applications, including diagnostic tools and therapeutic strategies . For instance, understanding the biological properties and functions of different molecules can lead to the development of new treatments and diagnostic methods, improving healthcare outcomes.
